Sina Pharmaceuticallive Class 4 - CHO Cell Enhanced Upstream Process Introduction.

In recent years, the pharmaceutical industry policy has been continuously introduced, consistency evaluation, China's accession to ICH, MAH implementation, drug clinical trial data verification and other accelerated industry survival of the fittest;
under the impetus of medical policy reform, the development of China's pharmaceutical industry is entering the fast lane of regulation.
under the background of "healthy China" as a national strategy, China is undergoing a transformation from a "medical power" to a "medical power".
and biopharmaceutical industry, as one of china's seven strategic emerging industries, is becoming a new engine of China's economic development.
through the regulation of policies, the input of supporting resources and the improvement of the construction of institutional mechanisms, China's biopharmaceutical industry has transitioned from "technological backwardness" to "keeping up with the international pace", in which the development of innovative drugs is particularly rapid.
has emerged a number of innovative biopharmaceutical companies, such as Baiji Shenzhou, Cinda Bio, Junshi Bio, as well as independent research and development of innovative drugs approved for listing.
want to sustain rapid growth, more top talent is needed and the overall level of employees is improved.
to provide a free and smooth communication platform for innovative pharmaceutical practitioners, Sina Pharma launched a special "New Knowledge Exchange" online live knowledge sharing platform, will focus on drug research and development target discovery, new technology development and application, process development and verification, drug clinical trial design and other hot topics, through strategy and case sharing, directly hit the research and development of production confusion.
course highlights: 1. Keep up with trends and share new technology development and applications; 2. Dry goods, focusing on case sharing and method analysis; 3. Tribute to innovation, tribute to pharmaceutical people; 4. The course is open, everyone can become a product manager, your valuable suggestions for live content are our ability to enhance, and you can apply to become a course instructor.
, July 27 (Monday), "New Zhihui" lesson 4 hit, Merck Life Sciences Process Solutions Upstream Product Application Manager Mr. Wang Yingchuan will share with you "CHO cell-enhanced upstream process introduction", look forward to your participation.
Share Theme: CHO Cell Enhanced Upstream Process Introduction 1. Industry Trends and Intensified Upstream Process 2. HCDC high density cell seed freezing technology 3. N-1perfusion process case and special medium 4. N-1 new cell retention device 5. Introduction Speaker of Irrigation Media Design and Screening Speaker: Mr. Wang Seechuan, Upstream Product Application Manager of Merck Life Sciences Process Solutions, 27 July 2020 19:30-20:30 Merck Life Sciences Process Solutions Upstream Product Application Manager Mr. Wang Yingchuan is currently the Upstream Product Application Manager of Merck Life Sciences Process Solutions Department, responsible for the media cell product sydgin products and technical related matters. before
joined Merck, Mr. Wang was engaged in antibody drug research and development, media product promotion and technical support in many well-known enterprises at home and abroad. as a senior technical expert, Mr.
has extensive knowledge of cell culture and media-related skills.
registration: this course is free of charge, scanning the next two-dimensional code to add Sina Pharmaceutical Live Assistant, registered.
(Note: Name and Company) follow-up more content sharing Please pay attention to sina pharma public number.
.